SURVYR

TGTX

TG Therapeutics, Inc.
$56.44
+$1.65 (3.01%)Oct 27 close
Health CareS&P 600 CompareTechnicals
Model valuationLeans expensiveDCF base $3
1M3M6M1Y2Y
-21%+4%+28%+52%+76%Oct 2025Oct 2026Apr 202652w high $59.3052w low $26.76
TGTXSPY
Wall St. Highest PT $86.00 (+52.4%) Wall St. Avg PT $69.71 (+23.5%)
$27$42$58$73$89POC $30Hi $86Avg $70
Underwater Drawdown %Max DD -22.5%Current -4.4%
0.0%-22.5%
Relative Strength vs SPY+54.0% vs SPYOutperforming
+74%0%-74%
1W
+$1.91 (3.50%)
1M
−$0.99 (1.72%)
3M
+$1.57 (2.86%)
6M
+$21.86 (63.22%)
YTD
+$26.63 (89.33%)
1Y
+$22.75 (67.53%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
8 analysts · mean score 1.50
1 = Strong Buy · 5 = Sell
Strong Buy675%
Buy112%
Hold00%
Underperform112%
Sell00%
Wall Street consensus · as of Oct 21, 2026
Analyst price targets
Current price$56.44
Average target$69.71
+$13.27 (+23.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$21.00
Median$75.00
High$86.00
12-month Wall Street target range · as of Oct 14, 2026
Recent analyst rating changes · 30
Reiterated
2026-09-01 · HC Wainwright & Co. reiterated Buy on TGTX
Reiterated
2026-08-07 · JP Morgan reiterated Overweight on TGTX
Reiterated
2026-07-27 · B. Riley Securities reiterated Buy on TGTX
Reiterated
2026-07-13 · HC Wainwright & Co. reiterated Buy on TGTX
Reiterated
2026-07-07 · B of A Securities reiterated Underperform on TGTX
Reiterated
2026-07-06 · HC Wainwright & Co. reiterated Buy on TGTX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Safe zone
Altman Z-score 5.3
Above 2.99 is the safe zone, below 1.81 the distress zone.
Quality
WeakAverageStrong
Average
Piotroski F-score 4 of 9
See the tests
  • ✓Positive net income
  • ✗Positive operating cash flow
  • ✓Return on assets improved
  • ✗Cash flow above net income
  • ✓Long-term debt / assets fell
  • ✗Current ratio improved
  • ✗No share dilution
  • ✗Gross margin improved
  • ✓Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$8.3B
P/E (last 12 months)19.7
P/E (next 12 months, estimated)20.0
52-week range$26.76 – $59.30
Revenue growth (latest quarter vs a year ago)+70.3%
Dividend yieldNo dividend
Analyst consensusStrong Buy (7)
Average analyst price target$69.71 (+24%)

What they do

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -1 (DCF counts double).
▼DCF (base case)below the price by 94%
•Forward P/E vs sector20.0x vs median 18.0x
•Piotroski F-score4/9
▲Altman Z5.3 (safe)
▲Net debt / EBITDA1.4x
▲Analyst target+24% (7 analysts)

Discounted cash flow

Bear
$1
-98%
growth 18% · disc. 14.0% · term. 2.0%
Base
$3
-94%
growth 30% · disc. 13.0% · term. 2.5%
Bull
$6
-88%
growth 38% · disc. 12.0% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Today's price assumes free cash flow grows more than 50% a year for 10 years.
Implied
>50%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
>150%/yr
Revenue, last 5 yrs
>150%/yr
Same inputs as the DCF above: trailing free cash flow 0.0B, 13.0% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.80 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 31.2× · 22nd pct
 19.7×
cheaper
Forward P/E
sector median 18.0× · 60th pct
 20.0×
pricier
EV / EBITDA
sector median 16.2× · 96th pct
 62.2×
pricier
Price / sales
sector median 3.3× · 90th pct
 10.4×
pricier
Price / book
sector median 3.5× · 92nd pct
 13.7×
pricier
FCF yield
sector median 4.0% · 12th pct
 0.2%
pricier

Forward EPS $2.71 vs trailing $2.75 (-2% expected growth). Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
82.4%
Operating margin
17.1%
FCF margin
2.2%
Net margin
55.2%
Return on equity
73.1%
Return on invested capital
17.1%
Net debt / EBITDA
1.4×
Current ratio
4.3×
Interest cover
3.6×
Cash conversion (OCF/NI)
0.0×
Piotroski F-score 4/9 · last two fiscal years
✓ Positive net income✗ Positive operating cash flow✓ Return on assets improved✗ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 5.3 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$70
+24%
Analysts
7
Strong Buy
Range
$21–$86
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$616.3M$447.2M$-25.0M
2024$329.0M$23.4M$-40.6M
2023$233.7M$12.7M$-31.4M
2022$2.8M$-223.8M$-176.2M
2021$6.7M$-348.1M$-296.0M
2020$152.0K–$-214.9M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +504.9%.

For information only · Important disclosures

Grades vs sector

Momentum
81st percentile in sector
A-
12-1 return: +60.4%
Percentile within its GICS sector across the S&P 1500.
Growth
96th percentile in sector
A+
Revenue growth (YoY): +70.3%
Percentile within its GICS sector across the S&P 1500.
Value
22nd percentile in sector
D
Forward E/P: 5.0% · EBITDA/EV: 1.7%
Percentile within its GICS sector across the S&P 1500.
Profitability
98th percentile in sector
A+
Profit margin: +55.2% · Return on equity: +100.3%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Held by 1 of 7 live models: SURVYR. Long Book.

SURVYR. Long Book
4.9% of the book · Core sleeve
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 36 of 589 · 12-month momentum 47.4%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
Why it's in the SURVYR. Long Book

Picked for this research portfolio at the Oct 21, 2026 close (Core group, Biotech & health).

What would knock it out: Weights are fixed and there is no rebalance rule. Any change would be dated and shown here.

Earnings & events

TGTX earningsNext report in 5 days
Next report · quarter Sep 2026
Mon Nov 2, 2026Before the open
EPS consensus$0.26 range $0.19–$0.35
Revenue consensus$245.4M 8 analysts
Last 4 quarters · EPS vs estimate
Aug 3, 2026$0.05est $0.44−88.6%Below estimates
May 6, 2026$0.18est $0.28−35.1%Below estimates
Feb 26, 2026$0.14est $0.33−57.5%Below estimates
Nov 3, 2025$0.16est $0.22−26.3%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-25 10:39:36 ET
24-1125-0325-0525-0825-1126-0226-0526-080.000.44
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$240.3M+70.3%
2026-03-31$204.9M–
2025-12-31$192.6M–
2025-09-30$161.7M–
2025-06-30$141.1M–

News & catalysts

More news
3 Healthcare Stocks To Watch In October 2026
Simply Wall St. · Oct 24
TGTX Stock Bucks Broader Biotech Selloff As Multiple Sclerosis Therapy Shows Promising Early Results — Here’s What Investors Need To Know
Stocktwits · Oct 23
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
Zacks · Oct 23
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
Business Wire · Oct 23
Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings
Zacks · Oct 23
Rating changes
Reiterated
2026-09-01 · HC Wainwright & Co. reiterated Buy on TGTX
Reiterated
2026-08-07 · JP Morgan reiterated Overweight on TGTX
Reiterated
2026-07-27 · B. Riley Securities reiterated Buy on TGTX
Reiterated
2026-07-13 · HC Wainwright & Co. reiterated Buy on TGTX
Reiterated
2026-07-07 · B of A Securities reiterated Underperform on TGTX
Reiterated
2026-07-06 · HC Wainwright & Co. reiterated Buy on TGTX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Charney Laurence N
Director · 2026-09-10
Sell
$274.8K
None
None · None
Sell
–

Stats refreshed 2026-10-25 10:39:36 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026